Theraclion News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.02.18	Theraclion Sells First Echopulse® System to Catalonia, Spain (Businesswire)
08.02.18	Theraclion Accelerates its Growth in 2017 (Businesswire)
07.02.18	Theraclion announces the reinforcement of its Board of Directors with the nomination of a new Non-Executive Director: Mister Renaud Saleur (Businesswire)
24.01.18	THERACLION Reports First Presentation of Results for Breast Cancer Strategy (Businesswire)
09.01.18	The French HealthTech Theraclion Presents Its Echopulse at CES 2018 (Businesswire)
08.01.18	Theraclion Reports Significant Milestone Achievement with Its Immunotherapy Breast Cancer Strategy (Businesswire)
21.12.17	First Patient Treatments by Theraclion’s Echopulse® in Poland (Businesswire)
18.12.17	First 5 Theraclion Echopulse Systems Delivered to China (Businesswire)
13.12.17	Theraclion Announces Reimbursement to 15 Million Covered German Lives (Businesswire)
11.12.17	Theraclion Achieves 2 Sales from Russia and Eastern Europe (Businesswire)
20.11.17	THERACLION’S Echopulse® New Clinical Data to Be Presented during RSNA by the University of Virginia (Businesswire)
15.11.17	Theraclion and Lead Investigator Presented Preliminary Results of Echotherapy In the Treatment of Varicose Veins (Businesswire)
06.11.17	Theraclion to Host Webinar to Discuss Preliminary Results of Echotherapy in the Treatment of Varicose Veins (Businesswire)
03.11.17	Distribution of the Share Capital of Theraclion (Businesswire)
26.10.17	Theraclion Makes Substantial Progress towards Market Access for Echopulse® in The US (Businesswire)
17.10.17	Theraclion Raises €4.2 Million Through Private Placement with Institutional Investors (Businesswire)
16.10.17	Theraclion Announces Study in Non-Invasive Varicose Vein Treatment and the Launch of a Private Placement (Businesswire)
09.10.17	Theraclion Announces Exclusive Distribution Agreement with EDAP TMS France (Businesswire)
27.09.17	Theraclion Extends Market Access and Regulatory Approval (Businesswire)
25.09.17	Theraclion Announces Important Steps towards Mainstream in Key Markets Germany and Hong Kong, China (Businesswire)
22.09.17	Theraclion comments on its 2017 half-year results (Businesswire)
11.09.17	Theraclion and Co-Lead Investigator Discuss Rationale and Design of First Clinical Trial Combining Echotherapy and Imunotherapy to Treat Metastatic Breast Cancer (Businesswire)
28.08.17	THERACLION Reports Publication of Promising Clinical Trial Results in a New Thyroid Indication (Businesswire)
22.08.17	Theraclion to Host Conference Call to Discuss First Immuno-Oncology Metastatic Breast Cancer Trial Combining Pembrolizumab and Echotherapy (Businesswire)
19.07.17	Theraclion Announces Expansion of Echotherapy Reimbursement Coverage to 14 Million Lives in Germany (Businesswire)
12.07.17	Theraclion’s Echopulse® Covered by French National Health Insurance for the Treatment of Breast Fibroadenomas (Businesswire)
09.01.17	Theraclion Strengthens Market Position of Echopulse® in Germany (Businesswire)
07.12.16	First Acquisition of Theraclion’s Echopulse® in Switzerland (Businesswire)
28.11.16	Theraclion Announces First Echotherapy System in the UK Dedicated to the Treatment of Thyroid Nodules (Businesswire)
18.10.16	Theraclion’s Half Year Results 2016 (Businesswire)
26.09.16	New Clinical Data Strongly Support the Safety and Efficacy of Theraclion’s Echotherapy System (Businesswire)
07.09.16	Theraclion to Present at the 18th Annual Rodman & Renshaw Global Investment Conference (Businesswire)
06.09.16	Major German Insurance Company in AOK Group Initiates Reimbursement Coverage of Theraclion’s Echotherapy (Businesswire)
31.08.16	First Data Generated in U.S. Support Theraclion’s Echotherapy System (Businesswire)
08.07.16	Theraclion Achieves Strong Sales and Business Development Momentum in H1 2016 (Businesswire)
29.06.16	Theraclion: 1st Echotherapy Centers for Benign Thyroid Nodules in Italy (Businesswire)
24.06.16	Initial Feedback Received from France's National Health Authority HAS in Relation to Theraclion’s Forfait Innovation Application (Businesswire)
14.06.16	Theraclion: Large private German clinic is now offering Echotherapy to patients (Businesswire)
08.06.16	Theraclion: New Clinical Study Results Reinforce Echotherapy Efficacy in Breast Fibroadenoma (Businesswire)
24.05.16	Theraclion: Strong Clinical Adoption Confirmed: +115% Growth in Treatment Numbers Driven by German and Asian Thyroid Market (Businesswire)
18.05.16	Theraclion's Combined Ordinary and Extraordinary Shareholders' General Meeting (Businesswire)
02.05.16	Large Chinese Biotech & Pharmaceutical Group Acquires 8% of Theraclion Shares, as Part of a Private Placement with Institutional Investors (Businesswire)
19.04.16	Tübingen University Publishes Positive Results on Echotherapy Breast Fibroadenoma Clinical Trial and Enters a Commercial Agreement with Theraclion (Businesswire)
29.03.16	Theraclion: 2015 Annual Results (Businesswire)
21.03.16	Extended Number of Patients Benefiting from Coverage for Echopulse® Treatments in Germany (Businesswire)
10.03.16	Growing Number of Echopulse® Treatments Confirms Theraclion’s Strategy (Businesswire)
08.02.16	Theraclion: First Patients Treated in Routine Clinical Practice in the UK (Businesswire)
26.01.16	Theraclion, First Company to Submit an Application for « Forfait Innovation » (Businesswire)
11.01.16	Theraclion Doubles Its Annual Sales for 2015 (+120% vs. 2014) (Businesswire)
21.12.15	First Echopulse® System in Switzerland (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’943.00	3.27 %	K V
Novartis	91.49	1.36 %	K V
Nestle	75.58	1.21 %	K V
Swiss Re	139.40	0.98 %	K V
Roche Hldg G	277.20	0.84 %	K V
Holcim	89.88	-1.47 %	K V
CieFinRichemont	169.00	-1.57 %	K V
Logitech Intl	80.56	-2.38 %	K V
Part Grp Hldg	1’352.00	-2.70 %	K V
ABB	51.28	-5.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Theraclion

Aktien Top/Flop

Meistgelesene Nachrichten